Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MND-2119 vs Epadel Phase 3 Trial in Hyperlipidemia
jRCT2080224069Phase 3Completed
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of icosapent in hyperlipidemia (3 arms). Primary endpoints: Efficacy non-inferiority of MND-2119 2 g/day vs Epadel 1.8 g/day and Efficacy superiority of MND-2119 4 g/day vs MND-2119 2 g/day. Started Oct 2018; status: completed.
02
Drugs
icosapent
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on jRCT2080224069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224069.